<DOC>
	<DOCNO>NCT00003743</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill neuroblastoma cell . PURPOSE : Phase II trial study effectiveness interleukin-2 treat child stage IV neuroblastoma receive induction therapy peripheral stem cell transplantation .</brief_summary>
	<brief_title>Interleukin-2 Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum dose administer ambulatory setting among three dose regimens child stage IV neuroblastoma . II . Determine high tolerate level sustained increase NK-cell number observe . III . Determine type , duration , reversibility side effect three dose level . IV . Confirm choose dose level . OUTLINE : This randomize , parallel , open label , multicenter study . Part I : Patients receive one three dose interleukin-2 ( IL-2 ) subcutaneously begin 20 40 day follow autologous stem cell reinfusion . IL-2 administer 5 consecutive day every 14 day 3 month , total 6 course . Cohorts 5 patient enter dose level IL-2 maximum tolerate dose ( MTD ) determine . The MTD define dose 3 patient experience dose limit toxicity . Part II : Additional patient receive IL-2 dose level MTD . These patient stratify accord prior therapy ( melphalan plus megatherapy v total body irradiation meta-iodobenzylguanidine scan plus melphalan v busulfan contain regimen ) . Patients follow 1 week . PROJECTED ACCRUAL : Approximately 25 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV neuroblastoma At least stable disease modern induction regimens megatherapy follow autologous stem cell reinfusion PATIENT CHARACTERISTICS : Age : Over 1 Performance status : Lansky 80100 % Life expectancy : Not specify Hematopoietic : Lymphocyte count least 500/mm3 Platelet count least 30,000/mm3 Hemoglobin least 8 g/dL ( least 1 week since transfusional support ) Blood coagulation less 25 % upper limit normal ( ULN ) age ( WHO grade 0 ) Hepatic : Bilirubin le 25 % ULN age ( WHO grade 0 ) Renal : Creatinine le 25 % ULN age ( WHO grade 0 ) Cardiovascular : No significant history current evidence cardiovascular disease ( e.g. , uncontrolled hypertension , serious arrhythmia ) Normal shorten fraction cardiac ultrasonography Normal ECG Other : No evidence active infection Normal chest xray Normal brain CT scan No concurrent disease second primary malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent immunotherapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroids hormonal therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : At least 30 day since prior investigational drug device No concurrent investigational drug , agent , device</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>